620 related articles for article (PubMed ID: 28241187)
21. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
22. Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency.
Polom K; Böger C; Smyth E; Marrelli D; Behrens HM; Marano L; Becker T; Lordick F; Röcken C; Roviello F
Eur J Surg Oncol; 2018 May; 44(5):626-631. PubMed ID: 29545085
[TBL] [Abstract][Full Text] [Related]
23. Microsatellite instability in colon cancer: A single center experience from North India.
Arora S; Adhikari N; Rathi AK; Singh K; Sakhuja P
J Cancer Res Ther; 2022; 18(3):656-660. PubMed ID: 35900537
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
25. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
[TBL] [Abstract][Full Text] [Related]
26. Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts.
Quaas A; Biesma HD; Wagner AD; Verheij M; van Berge Henegouwen MI; Schoemig-Markiefka B; Pamuk A; Zander T; Siemanowski J; Sikorska K; Egthuijsen JMP; Meershoek-Klein Kranenbarg EM; van de Velde CJH; Buettner R; Alakus H; Cats A; Ylstra B; van Laarhoven HWM; van Grieken NCT
Eur J Cancer; 2022 Sep; 173():95-104. PubMed ID: 35863110
[TBL] [Abstract][Full Text] [Related]
27. High homogeneity of MMR deficiency in ovarian cancer.
Fraune C; Rosebrock J; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Höflmayer D; Schmalfeldt B; Müller V; Wölber L; Witzel I; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Clauditz TS; Wilczak W; Sauter G; Steurer S; Burandt E
Gynecol Oncol; 2020 Mar; 156(3):669-675. PubMed ID: 31924330
[TBL] [Abstract][Full Text] [Related]
28. An exploration of gastric cancer with heterogeneous mismatch repair status.
Wang X; Jiang K; Hu Y; Zhao X; Yin L; Diao X; Ma X; Xu Y; Bai Y; Zhang Y; Li Z; Sun Y
Virchows Arch; 2023 Mar; 482(3):517-523. PubMed ID: 36754896
[TBL] [Abstract][Full Text] [Related]
29. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.
Smyth EC; Nyamundanda G; Cunningham D; Fontana E; Ragulan C; Tan IB; Lin SJ; Wotherspoon A; Nankivell M; Fassan M; Lampis A; Hahne JC; Davies AR; Lagergren J; Gossage JA; Maisey N; Green M; Zylstra JL; Allum WH; Langley RE; Tan P; Valeri N; Sadanandam A
Ann Oncol; 2018 Dec; 29(12):2356-2362. PubMed ID: 30481267
[TBL] [Abstract][Full Text] [Related]
30. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.
Kim JW; Cho SY; Chae J; Kim JW; Kim TY; Lee KW; Oh DY; Bang YJ; Im SA
Cancer Res Treat; 2020 Oct; 52(4):1178-1187. PubMed ID: 32599979
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.
Nie RC; Chen GM; Yuan SQ; Kim JW; Zhou J; Nie M; Feng CY; Chen YB; Chen S; Zhou ZW; Wang Y; Li YF
Ann Surg Oncol; 2022 Apr; 29(4):2324-2331. PubMed ID: 34796431
[TBL] [Abstract][Full Text] [Related]
33. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
34. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability.
Kohlruss M; Grosser B; Krenauer M; Slotta-Huspenina J; Jesinghaus M; Blank S; Novotny A; Reiche M; Schmidt T; Ismani L; Hapfelmeier A; Mathias D; Meyer P; Gaida MM; Bauer L; Ott K; Weichert W; Keller G
J Pathol Clin Res; 2019 Oct; 5(4):227-239. PubMed ID: 31206244
[TBL] [Abstract][Full Text] [Related]
35. Alterations of DNA mismatch repair proteins and microsatellite instability levels in gastric cancer cell lines.
Yao Y; Tao H; Kim JJ; Burkhead B; Carloni E; Gasbarrini A; Sepulveda AR
Lab Invest; 2004 Jul; 84(7):915-22. PubMed ID: 15133479
[TBL] [Abstract][Full Text] [Related]
36. [MICROSATELLITE INSTABILITY AND SURVIVAL IN PATIENTS WITH ENDOMETRIAL CANCER.].
Ivanova K; Stoyanov S; Vlaykova T; Gulubova M
Akush Ginekol (Sofiia); 2016; 55(5):21-28. PubMed ID: 29790711
[TBL] [Abstract][Full Text] [Related]
37. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
Bendardaf R; Lamlum H; Ristamäki R; Korkeila E; Syrjänen K; Pyrhönen S
Acta Oncol; 2008; 47(6):1046-53. PubMed ID: 17943475
[TBL] [Abstract][Full Text] [Related]
38. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
[TBL] [Abstract][Full Text] [Related]
39. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in Uterine Endometrioid Carcinoma.
Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
[TBL] [Abstract][Full Text] [Related]
40. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
